{"entity":{"id":"nct02598349","kind":"trial","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","aka":[],"tldr":"A phase 2 trial of capecitabine in pancreatic cancer, run by Proton Collaborative Group, now recruiting.","summary":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas is a phase 2, interventional study registered as NCT02598349 by Proton Collaborative Group, with a registry enrolment figure of 60 participants, started 2016-04 and due to reach its primary completion in 2039-10. Interventions recorded: Proton Radiation; Capecitabine; Surgical resection. Conditions listed: Pancreatic Cancer. Primary outcome: Overall survival at 12 months after radiation therapy. Pancreatic eligibility wording from the registry: \"* Biopsy proven unresectable adenocarcinoma of the pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02598349","url":"https://clinicaltrials.gov/study/NCT02598349"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","locally-advanced-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02598349","phase":"2","setting":"A Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma","sponsor":"Proton Collaborative Group","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02598349/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}